HumeCare+ review

What it is

The GLP-1 telehealth arm of Hume Health, the connected-scale company. The operating entity named in its Terms of Service is Hume Health Care LLC, a Delaware limited liability company, and the address in the site footer is 8 The Green #24578, Dover, Delaware — a registered-agent suite rather than a clinic. Hume is explicit in its own terms that it is not the provider of care: it describes itself as a technology and administrative services platform only, with all medical evaluation, prescribing and ongoing treatment carried out by an independent third-party network of licensed physicians it calls the Clinical Network. Your clinical relationship is with that network under its own patient agreements, not with Hume. That is an honest structure, honestly disclosed, and more services on this board should state it as plainly.

How it works

Entry is an online questionnaire rather than a booked appointment, after which eligible users are connected to the Clinical Network. The terms provide for two medication routes: FDA-approved branded GLP-1s filled through standard retail or mail-order pharmacies, and custom-compounded preparations filled through licensed compounding pharmacies. Neither the Clinical Network nor any pharmacy is named anywhere we could find, which is the standard weakness on this board rather than an unusual one. The site does name its medical leadership, which many competitors do not: a Chief Medical Officer, Dr. Aaron Carter, MD, and a second clinician listed as a pharmacist independent prescriber — a British regulatory title with no US equivalent, on a service that operates only in the United States. Membership renews automatically, monthly plans monthly and annual plans annually, and cancellation has to be submitted through the account page or support email at least 48 hours before the renewal date. Liability is capped at the greater of $100 or twelve months of fees, and the terms carry a binding arbitration clause with a class-action and jury-trial waiver.

Pricing transparency

Nothing HumeCare+ publishes openly carries a price. We rendered the homepage and it contains zero dollar figures; the storefront's product endpoint returns an empty list; the only route to a number is a multi-step medical questionnaire. Walk that questionnaire and the pricing is, in itself, perfectly reasonable: compounded semaglutide by injection is $199 a month, oral semaglutide is also $199, and tirzepatide compounded with vitamin B12 and glycine is $299. Each is billed monthly and each is labeled "Free Shipping - Cancel anytime," with medication and prescription, provider consultation, shipping and 24/7 clinical support included. There is no minimum term. That last point matters, because the terms HumeCare+ gives its affiliate partners state that a three-month commitment is required — and that condition appears on no consumer surface we could find. The checkout page contains no instance of the words renew, intro, commitment or billed. What the checkout does carry is pressure. Each price sits beside a struck-through figure — $299 against semaglutide, $399 against tirzepatide — that the page never explains, with no renewal language to say whether those are real standing rates or simply anchors. Above them runs a countdown clock reserving "your offer" for the next few minutes, under the heading SAVE $100 TODAY. A price that is fair on its own terms is being sold as though it might vanish. One further charge is documented in the Terms of Service and does not appear at checkout: a clinical consultation fee assessed at enrollment and again at every refill, collected on behalf of the Clinical Network, non-refundable in all circumstances and never quantified — while the checkout lists "provider consultation" among the things your membership already includes. To the service's credit, the fee does cover the medication itself where one is prescribed, the program is HSA/FSA eligible, and the Hume Pod, which the company values at $350, is included rather than sold separately.

Branded vs compounded

Three products, and you only learn that at the end of the funnel: compounded semaglutide by injection, oral compounded semaglutide, and compounded tirzepatide formulated with vitamin B12 and glycine. The open marketing site names semaglutide alone, so the tirzepatide line — the more potent of the two molecules, and the more expensive — is invisible until you have handed over your height, weight, date of birth and email. No dose is published at any point. Not on the homepage, not in the terms, and not on the checkout page where you are asked to commit to a monthly charge; there is not one milligram figure on the entire path, and the page says only that final dose and formulation are set by your provider. The additives are a real differentiator rather than filler: glycine for sleep and muscle protection, B6 and B12 against nausea and fatigue. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, efficacy or manufacturing quality, and HumeCare+ says so plainly at the point of sale, alongside an unusually direct warning about the risk of thyroid C-cell tumors and medullary thyroid carcinoma and what symptoms should send you to a provider. That is better safety disclosure than most of this board manages. It sits oddly, though, beside an earlier screen in the same funnel headed "No Side Effects. Just Results." One marketing claim also fails to reconcile with the evidence the site itself cites: the homepage leads with losing "up to 21.5%" of body weight, but that figure is not attributed to any of the five references at the foot of the page. Those references are otherwise real published work, including the STEP 1 semaglutide trial and a 2024 review of lean-mass change on GLP-1 therapies. A third is Hume's own unpublished internal analysis of 8,000 members, methodology available on request — reasonable to run, and not a substitute for a controlled trial. The funnel makes a second such claim, that you will lose twice as much weight as on your own, sourced only to "a clinical study over 12 weeks of active HumeCare+ users": unnamed, uncited and, by its own description, single-arm.

Pros and watch-outs

The evidence behind what HumeCare+ prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• What the semaglutide weight-loss trials actually showed

  STEP 1, STEP 4, and SELECT — the efficacy, the rebound, and the cardiovascular signal, read straight from the primary literature.

• GLP-1 medications and muscle: what the body-composition data actually show

  Some of the weight lost is lean mass — but the substudies show fat falls faster, the ratio improves, and resistance training plus protein is what protects muscle.

How HumeCare+ compares

A few alternatives worth a look, depending on what you’re optimizing for.

• He & She MD

  Flat per-dose GLP-1 pricing across injectable and oral, if you read the ladder before the banner

  See He & She MD →
• Novi

  All-in transparent pricing with clinician support and shipping included

  See Novi →
• Superior Remedies

  A published microdose program with nothing charged unless you are approved

  See Superior Remedies →